Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma.
The New England journal of medicine（2023）
摘要
In previously treated patients with fusion or rearrangement-positive intrahepatic cholangiocarcinoma, the use of futibatinib, a covalent FGFR inhibitor, led to measurable clinical benefit. (Funded by Taiho Oncology and Taiho Pharmaceutical; FOENIX-CCA2 ClinicalTrials.gov number, NCT02052778.).
更多查看译文
关键词
intrahepatic cholangiocarcinoma
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要